JACY BARKER: Open Payments
NPI 1407281272 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,474 in 148 payments from 12 companies in 2025. Trend: 2023 $2,003 · 2024 $1,614 · 2025 $2,474
Food & beverage: $2,474
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $400 |
| Neurocrine BioSciences, Inc. | 22 | $386 |
| Otsuka America Pharmaceutical, Inc. | 30 | $353 |
| Teva Pharmaceuticals USA, Inc. | 18 | $326 |
| Janssen Pharmaceuticals, Inc | 21 | $318 |
| Vanda Pharmaceuticals Inc. | 11 | $236 |
| ABBVIE INC. | 9 | $159 |
| Alkermes, Inc. | 10 | $149 |
| Axsome Therapeutics, Inc. | 4 | $74 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
Products named: CAPLYTA, INGREZZA, INVEGA SUSTENNA, UZEDY, REXULTI, VRAYLAR, FANAPT, ARISTADA.
Industry payments across KS — which companies pay providers there.
